ReviewCancer science2026
tRNA-Derived Small RNAs in Digestive Cancers: From Translational Regulation to Immune and Extracellular Communication.
Review in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transfer RNA-derived small RNAs (tsRNAs), comprising tRNA-derived fragments (tRFs) and stress-induced tRNA halves (tiRNAs), have increasingly been recognized as an important regulatory class in gastric cancer (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), and pancreatic cancer/pancreatic ductal adenocarcinoma (PC/PDAC). Research in this field has expanded from expression profiling and liquid biopsy to non-canonical translational control, metabolic adaptation, therapy resistance, immune-associated remodeling, and extracellular-vesicle (EV)-related communication. The most intensively studied and mechanistically developed area currently lies at the intracellular level. In digestive system tumors, tsRNAs can act through EIF4 displacement, AGO2/RISC-dependent silencing, direct target repression, and ribosome-associated interactions, with some of these mechanisms validated in animal models. Beyond direct regulation of gene expression, tsRNAs can also influence tumor metabolic state and thereby contribute to chemo- and radio-resistance. By contrast, studies directly examining the effects of tsRNAs on immune-cell populations remain relatively limited, and work on EV-mediated systemic propagation still largely focuses on vesicle association and biomarker value. Functional delivery and recipient-cell effects require further clarification. Among the currently summarized studies, pancreatic-derived signaling that conditions the hepatic niche represents one of the few examples approaching a cross-organ functional model. This review discusses the major functional layers of tsRNAs in digestive system tumors, beginning with the relatively mature intracellular mechanisms and then extending to emerging immune, extracellular/systemic, and host-microbe research. We also identify key unresolved problems, including nomenclature standardization, modification-aware sequencing, criteria for EV functional delivery, causal validation of microbiota-derived tsRNAs, and prospective biomarker validation against benign and inflammatory disease controls.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.